OMRON Healthcare aids NHS clinicians with groundbreaking remote patient monitoring platform for hypertension, OMRON Hypertension Plus

    Hypertension Plus marks significant step towards the future of remote and patient empowered healthcare
    It has the potential to relieve GPs from up to a third of hypertension appointments

“Thousands of heart attacks and strokes can be prevented by more people knowing their blood pressure.”
- Duncan Selbie, Public Health England

Hoofddorp, Netherlands. 23 March, 2021 - OMRON Healthcare, a global leader in health monitoring and therapy, presents today OMRON Hypertension Plus in the UK, a groundbreaking remote patient monitoring (RPM) platform for hypertension, designed to help NHS clinicians to manage a patient’s medication plan remotely, based on the patient’s home blood pressure results. The system’s development marks another positive step in the overall digital transformation of the NHS.

Hypertension Plus generates a tailored medication plan for the patient, which is recommended directly to the clinician, who can then easily and quickly accept or modify plans at their discretion and inform patients immediately over a dedicated mobile app. Over time, Hypertension Plus collates the patient’s blood pressure readings along with other key health parameters and inform clinicians when it’s time for their patients to progress in their treatment plan or if there is any urgent action to be taken. These recommendations are underpinned by an exclusive algorithm founded on clinically proven medication titration techniques for hypertension, based on current National Institute for Health and Care Excellence (NICE) guidelines.

Over 150 UK practices are included in the roll out phase – managed by clinical commission groups (CCGs) – with further CCGs encouraged to join the initiative. This, combined with a wealth of home blood pressure devices made available through the NHS at Home initiative, will equip practitioners and patients alike with the latest digital tools to manage hypertension. Once rolled out across the UK, it is estimated that Hypertension Plus will save significant GP time and that up to a third of appointments for hypertension could be freed up, according to estimation by the National Association of Primary Care (NAPC).

The platform incorporates a recommended activity programme for patients. As well as providing a regular cadence of readings, patients will be asked to complete a measurement week once per month, during which they will provide readings in the morning and evening each day. From these, the platform is able to determine how the patient is responding to their treatment and recommend personalized plan updates. The app also supports patients with insights on their condition to improve medication adherence and encourage beneficial lifestyle changes in the pursuit of healthier and more active lives.

The design of Hypertension Plus was shaped by the TASMINH home blood pressure trials, a clinical study that proved the potential to reduce blood pressure through self-management and remote adjustment of medications1. In particular, TASMINH4 showed a significant (4.7mmHg) blood pressure reduction in systolic after 12 months of using a telemonitoring platform to titrate when compared to usual care pathways.

Going For Zero cardiovascular events

Drawing on its proven track record in hypertension management, OMRON developed OMRON Hypertension Plus to help relieve pressure on the healthcare systems. In words of Paul Stevens, Connected Services and Solutions Director of OMRON Healthcare Europe, “even before the current pandemic, long-term chronic disease management was creating significant strain on healthcare systems, with a shortage in healthcare professionals the norm across Europe. Hypertension Plus enables doctors to adjust the intake of prescription medication remotely and empowers patients to actively manage their condition to achieve a significant blood pressure reduction, which may result in significantly lower rates of heart attacks and strokes throughout the UK and Europe”.

Dr. Nav Chana, Clinical Director of National Association of Primary Care (NAPC) said that “covid-19 has highlighted more than ever the importance of managing cardiovascular risk factors particularly in target populations. Technologies such as Hypertension Plus can help primary care clinicians to appropriately target their workload so that they are using their skills most appropriately and able to support patients with the resources they need to manage their blood pressure”.

According to André Van Gils, CEO & President of OMRON Healthcare Europe, “new research shows both healthcare practitioners and patients are embracing this move to digital2, and desire to adopt these solutions is skyrocketing. Hypertension Plus fills a central void in hypertension management, enabling effective decision making for healthcare professionals and bringing our zero cardiovascular event promise into concrete action”.

Hypertension Plus is interoperable with GP IT systems, streamlining the onboarding approach, minimising the workload of practices transferring to a new system, and GDPR compliant.

COVID-19 Drivers

The COVID-19 pandemic is having a sustained impact on healthcare systems. As a patient cohort that requires regular check-ups and readings taken, Hypertension Plus has the potential to provide both resourcing relief to NHS staff, as well as regular remote input of new readings. Reasons for improved hypertensive monitoring include:

  • The No. 1 contributing risk factor for global death is high blood pressure3
  • It rarely has noticeable symptoms but drastically increases risk of serious problems such as heart attacks and strokes4
  • High blood pressure affects approximately 1 in 4 adults worldwide and over 150 million people in Europe specifically5
  • As a result, cardiovascular disease kills more than 18 million people every year, accounting for a third of all global deaths6
  • With improved and consistent monitoring of cardiovascular state of health world-wide, up to 80% (14.4 million) of these deaths could be preventable7
  • Peer reviewed studies show “a significantly lower number of deaths” when using remote patient monitoring to monitor for heart failure8
  • Most GP surgeries, hospitals, mental health services and community care services now offer video consultations9
  • Over 25,000 people now access doctors remotely a day10; involving further technology is the next logical step

About OMRON Healthcare

Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.

Throughout its 87-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.

OMRON Healthcare is the No. 1 brand recommended by cardiologists in Europe for blood pressure monitors and the Global No. 1 brand in nebulisers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.

OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.

OMRON Healthcare Europe B.V.
Scorpius 33, 2132 LR Hoofddorp, The Netherlands
+31 (0)23 55 44 700,


1 Lancet. 2018 Mar 10;391(10124):949-959.
2 Retrieved from:
3 WHO p.V.
5 Ramzy, I. R. Definition of hypertension and pressure goals during treatment. European Society of Cardiology. 2019
6 Thomas R Frieden, Saving 100 million lives by improving global treatment of hypertension and reducing cardiovascular disease risk factors,
7 American Heart Association
8 Journal of the American College of Cardiology A Meta-Analysis of Remote Monitoring of Heart Failure Patients
10 Evening Standard